If Geron had a buyer for its human embryonic stem cell business, volume would be up. If the deal was good the shares price would go up. If not so good the share price would go down. The share price was $1.73 at Friday's close. I'm guessing Geron will get pennies on the the dollar, for what it is worth. Maybe a little money up front with a large % of royalties down the road. What Geron needs is a large up front payment [$200 million and a small % of royalties] so they can stay in business. Again any big price move over $2.00 I will sell a few shares and sell a few covered calls. The avg. volume for the short week was only 883,200 shares, the ten day avg. was 996,172 shares, three month avg. was 1,493,840 shares
ACTC closed at 0.145 cent Friday. Volume was down. End of February should have news on the Phase 1/2 clinical trial for dry age related macular degeneration using human embryonic stem cell- derived retinal pigment epithelial cells.
Good luck in this rigged casino,
No comments:
Post a Comment